What do you do when most trials suggest benefit for an intervention, but then a new trial suggests harm? We thought steroids in pneumonia was a settled question, but REMAP-CAP had other plans!
We also review a new RCT for BP targets in patients with hypertension and diabetes, a new aldosterone synthase inhibitor for hypertension, and reduced dose apixaban for cancer-associated thrombosis.
Hydrocortisone for Severe CAP (REMAP-CAP)
Predicting Benefit of Corticosteroids in Pneumonia
Intensive BP Control in Patients with Diabetes (BPROAD)
Lorundrostat for Uncontrolled Hypertension (ADVANCE-HTN)
Reduced Dose Apixaban for Cancer Associated Thrombosis (API-CAT)
Music from Uppbeat (free for Creators!):
https://uppbeat.io/t/soundroll/dope
License code: NP8HLP5WKGKXFW2R
View all episodes
By Stephen Jenkins, MD, Austin Rupp, MD
4.9
4343 ratings
What do you do when most trials suggest benefit for an intervention, but then a new trial suggests harm? We thought steroids in pneumonia was a settled question, but REMAP-CAP had other plans!
We also review a new RCT for BP targets in patients with hypertension and diabetes, a new aldosterone synthase inhibitor for hypertension, and reduced dose apixaban for cancer-associated thrombosis.
Hydrocortisone for Severe CAP (REMAP-CAP)
Predicting Benefit of Corticosteroids in Pneumonia
Intensive BP Control in Patients with Diabetes (BPROAD)
Lorundrostat for Uncontrolled Hypertension (ADVANCE-HTN)
Reduced Dose Apixaban for Cancer Associated Thrombosis (API-CAT)
Music from Uppbeat (free for Creators!):
https://uppbeat.io/t/soundroll/dope
License code: NP8HLP5WKGKXFW2R
171,949 Listeners
321 Listeners
553 Listeners
499 Listeners
763 Listeners
3,360 Listeners
112,934 Listeners
56,548 Listeners
1,156 Listeners
99,113 Listeners
78 Listeners
67 Listeners
426 Listeners
172 Listeners